Monthly Communication Report

Organization:	Innovative Medicines Canada/Médicaments novateurs Canada
Associated registration:	957857-371-133
Communication date:	2026-04-29
Posted date:	2026-05-14

Designated Public Office Holders who participated in the communication:	Sara  O’Connor, Director General Planning and Operations Directorate at Health Canada, Health Canada (HC) Ritu Banerjee, Assistant Deputy Minister Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED) Celia Lourenco, Associate Assistant Deputy Minister Health Products and Food Branch, Health Canada (HC) Pamela Aung-Thin , Assistant Deputy Minister Health Products and Food Branch, Health Canada (HC) Elizabeth  Wong, Senior Policy Advisor Treasury Board Of Canada Secretariat (TBS) Sony Perron, Deputy Minister Innovation, Science and Economic Development Canada (ISED) Annahat Kochar , Senior Policy Advisor Treasury Board Of Canada Secretariat (TBS) Manuela Tomic, Senior Policy Advisor Minister of Industry and Minister Responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED) Sandenga Yeba, Director of Policy & Deputy Chief of Staff Office of the Minister of Health, Health Canada (HC) Justine Frame, Policy Advisor Minister's Office, Health Canada (HC)
List of Details Subject matter Detail Health, Intellectual Property, International Trade, Research and Development, Science and Technology Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Federal-Provincial Relations, Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, National Security/Security, Research and Development, Science and Technology Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Responsible Officer who filed this communication report:	Bettina Hamelin
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.